Comparative Pharmacology
Head-to-head clinical analysis: ACCUPRIL versus ZESTORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUPRIL versus ZESTORETIC.
ACCUPRIL vs ZESTORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, thereby blocking conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing diuresis and reducing plasma volume.
10-40 mg orally once daily; initial dose 10 mg, titrate to target dose based on blood pressure response; maximum 80 mg/day.
Zestoretic (lisinopril/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: 10 mg/12.5 mg, 20 mg/12.5 mg, or 20 mg/25 mg orally once daily. Maximum dose: lisinopril 80 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Quinaprilat terminal elimination half-life is approximately 3 hours. In patients with renal impairment (CrCl <30 mL/min), half-life can be prolonged up to 10-25 hours, requiring dose adjustment.
Lisinopril: terminal half-life approximately 12 hours (accumulation half-life 13.8 hours in patients with normal renal function). Hydrochlorothiazide: terminal half-life 5.6–14.8 hours (mean 9.6 hours).
Primarily renal (about 60% as unchanged drug and 40% as metabolites, mainly quinaprilat), with biliary/fecal elimination accounting for less than 10%.
Lisinopril is excreted unchanged in urine; 100% renal elimination. Hydrochlorothiazide is excreted primarily by the kidney (≥95% as unchanged drug) via tubular secretion.
Category C
Category C
ACE Inhibitor
ACE Inhibitor + Diuretic